Name: Cognition Therapeutics, Inc. (CGTX) Financial Statements
Creator: FinSpry

Cognition Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Cognition Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
Operating Expenses
Research & Development	41.68	37.20	30.32	18.57	12.89
Selling, General & Administrative	12.29	13.53	13.23	10.03	4.52
Operating Expenses	53.97	50.72	21.33	11.15	17.41
Operating Income	-53.97	-50.72	-21.33	-11.15	-17.41
Other Income/Expense
Interest Income	0.00	0.00	0.00	0.00	0.00
Interest Expense	-0.03	-0.03	0.03	0.89	-1.75
Other Income/Expense	20.22	24.96	-0.04	0.33	11.45
Income
Income Before Tax	-33.97	-25.79	-21.40	-11.72	-7.84
Income Tax Expense	0.00	0.00	0.00	0.00	0.00
Net Income	-33.97	-25.79	-21.40	-11.72	-7.84
Net Income - Continuous Operations	-33.97	-25.79	-21.40	-11.72	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-53.86	-50.63	-21.13	-10.73	-17.31
EBIT	-53.97	-50.72	-21.37	-10.82	-17.41
Depreciation & Amortization	0.11	0.10	0.24	0.09	0.10
Earnings Per Share
Basic EPS	-1.00	-1.00	-1.00	-3.00	-24.00
Diluted EPS	-1.00	-1.00	-1.00	-3.00	-24.00
Basic Shares Outstanding	39.73	30.03	23.64	5.19	0.51
Diluted Shares Outstanding	39.73	30.03	23.64	5.19	0.51